Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 125

1.

Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma.

Bronte G, Rizzo S, La Paglia L, Adamo V, Siragusa S, Ficorella C, Santini D, Bazan V, Colucci G, Gebbia N, Russo A.

Cancer Treat Rev. 2010 Nov;36 Suppl 3:S21-9. doi: 10.1016/S0305-7372(10)70016-5. Review.

PMID:
21129606
[PubMed - indexed for MEDLINE]
2.

Analysis of EGFR, EML4-ALK, KRAS, and c-MET mutations in Chinese lung adenocarcinoma patients.

Xia N, An J, Jiang QQ, Li M, Tan J, Hu CP.

Exp Lung Res. 2013 Oct;39(8):328-35. doi: 10.3109/01902148.2013.819535. Epub 2013 Aug 6.

PMID:
23919423
[PubMed - indexed for MEDLINE]
3.

[Relevance of molecular alterations in histopathologic subtyping of lung adenocarcinoma based on 2011 International Multidisciplinary Lung Adenocarcinoma Classification].

Liu B, Shi SS, Wang X, Xu Y, Zhang XH, Yu B, Lu ZF, Wang JD, Zhou XJ.

Zhonghua Bing Li Xue Za Zhi. 2012 Aug;41(8):505-10. doi: 10.3760/cma.j.issn.0529-5807.2012.08.001. Chinese.

PMID:
23157740
[PubMed - indexed for MEDLINE]
4.

Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma.

Kosaka T, Yatabe Y, Onozato R, Kuwano H, Mitsudomi T.

J Thorac Oncol. 2009 Jan;4(1):22-9. doi: 10.1097/JTO.0b013e3181914111.

PMID:
19096302
[PubMed - indexed for MEDLINE]
5.

Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose.

Li H, Pan Y, Li Y, Li C, Wang R, Hu H, Zhang Y, Ye T, Wang L, Shen L, Sun Y, Chen H.

Lung Cancer. 2013 Jan;79(1):8-13. doi: 10.1016/j.lungcan.2012.09.018. Epub 2012 Oct 23.

PMID:
23098378
[PubMed - indexed for MEDLINE]
6.

Analysis of driver mutations in female non-smoker Asian patients with pulmonary adenocarcinoma.

Ren S, Kuang P, Zheng L, Su C, Li J, Li B, Chen X, Wang Y, KimCurran V, Liu L, Hu Q, Zhang J, Tang L, Zhou C.

Cell Biochem Biophys. 2012 Nov;64(2):155-60. doi: 10.1007/s12013-012-9384-8.

PMID:
22707299
[PubMed - indexed for MEDLINE]
7.

Reflex testing of resected stage I through III lung adenocarcinomas for EGFR and KRAS mutation: report on initial experience and clinical utility at a single center.

D'Angelo SP, Park B, Azzoli CG, Kris MG, Rusch V, Ladanyi M, Zakowski MF.

J Thorac Cardiovasc Surg. 2011 Feb;141(2):476-80. doi: 10.1016/j.jtcvs.2010.08.026. Epub 2010 Oct 8.

PMID:
20933246
[PubMed - indexed for MEDLINE]
8.

Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer.

Mitsudomi T, Yatabe Y.

Cancer Sci. 2007 Dec;98(12):1817-24. Epub 2007 Sep 20. Review.

PMID:
17888036
[PubMed - indexed for MEDLINE]
9.

Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).

Lim EH, Zhang SL, Li JL, Yap WS, Howe TC, Tan BP, Lee YS, Wong D, Khoo KL, Seto KY, Tan L, Agasthian T, Koong HN, Tam J, Tan C, Caleb M, Chang A, Ng A, Tan P.

J Thorac Oncol. 2009 Jan;4(1):12-21. doi: 10.1097/JTO.0b013e3181913e28.

PMID:
19096301
[PubMed - indexed for MEDLINE]
10.

Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer.

Chou TY, Chiu CH, Li LH, Hsiao CY, Tzen CY, Chang KT, Chen YM, Perng RP, Tsai SF, Tsai CM.

Clin Cancer Res. 2005 May 15;11(10):3750-7.

PMID:
15897572
[PubMed - indexed for MEDLINE]
Free Article
11.

Long-term response to gefitinib and crizotinib in lung adenocarcinoma harboring both epidermal growth factor receptor mutation and EML4-ALK fusion gene.

Chiari R, Duranti S, Ludovini V, Bellezza G, Pireddu A, Minotti V, Bennati C, Crinò L.

J Clin Oncol. 2014 Mar 20;32(9):e30-2. doi: 10.1200/JCO.2012.47.7141. Epub 2014 Jan 13. No abstract available.

PMID:
24419120
[PubMed - indexed for MEDLINE]
12.

Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma.

Marks JL, Broderick S, Zhou Q, Chitale D, Li AR, Zakowski MF, Kris MG, Rusch VW, Azzoli CG, Seshan VE, Ladanyi M, Pao W.

J Thorac Oncol. 2008 Feb;3(2):111-6. doi: 10.1097/JTO.0b013e318160c607.

PMID:
18303429
[PubMed - indexed for MEDLINE]
13.

Activation status of receptor tyrosine kinase downstream pathways in primary lung adenocarcinoma with reference of KRAS and EGFR mutations.

Hiramatsu M, Ninomiya H, Inamura K, Nomura K, Takeuchi K, Satoh Y, Okumura S, Nakagawa K, Yamori T, Matsuura M, Morikawa T, Ishikawa Y.

Lung Cancer. 2010 Oct;70(1):94-102. doi: 10.1016/j.lungcan.2010.01.001. Epub 2010 Feb 1.

PMID:
20117855
[PubMed - indexed for MEDLINE]
14.

Recurrent EML4-ALK-associated lung adenocarcinoma with a slow clinical course.

Murakami S, Yokose T, Saito H, Sakuma Y, Matsukuma S, Hasegawa C, Kondo T, Oshita F, Ito H, Tsuboi M, Nakayama H, Kameda Y, Noda K, Yamada K.

Lung Cancer. 2010 Sep;69(3):361-4. doi: 10.1016/j.lungcan.2010.05.019. Epub 2010 Jun 17.

PMID:
20659620
[PubMed - indexed for MEDLINE]
15.

A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALK fusion gene.

Tanaka H, Hayashi A, Morimoto T, Taima K, Tanaka Y, Shimada M, Kurose A, Takanashi S, Okumura K.

BMC Cancer. 2012 Nov 26;12:558. doi: 10.1186/1471-2407-12-558.

PMID:
23181703
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Going beyond EGFR.

Zimmermann S, Peters S.

Ann Oncol. 2012 Sep;23 Suppl 10:x197-203.

PMID:
22987962
[PubMed - indexed for MEDLINE]
17.

Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.

Sun Y, Ren Y, Fang Z, Li C, Fang R, Gao B, Han X, Tian W, Pao W, Chen H, Ji H.

J Clin Oncol. 2010 Oct 20;28(30):4616-20. doi: 10.1200/JCO.2010.29.6038. Epub 2010 Sep 20.

PMID:
20855837
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset.

Inamura K, Takeuchi K, Togashi Y, Hatano S, Ninomiya H, Motoi N, Mun MY, Sakao Y, Okumura S, Nakagawa K, Soda M, Choi YL, Mano H, Ishikawa Y.

Mod Pathol. 2009 Apr;22(4):508-15. doi: 10.1038/modpathol.2009.2. Epub 2009 Feb 20.

PMID:
19234440
[PubMed - indexed for MEDLINE]
Free Article
19.

Assessment of mutational profile of Japanese lung adenocarcinoma patients by multitarget assays: a prospective, single-institute study.

Serizawa M, Koh Y, Kenmotsu H, Isaka M, Murakami H, Akamatsu H, Mori K, Abe M, Hayashi I, Taira T, Maniwa T, Takahashi T, Endo M, Nakajima T, Ohde Y, Yamamoto N.

Cancer. 2014 May 15;120(10):1471-81. doi: 10.1002/cncr.28604. Epub 2014 Apr 3.

PMID:
24700479
[PubMed - indexed for MEDLINE]
20.

KRAS mutational testing in the selection of patients for EGFR-targeted therapies.

Garcia J, Riely GJ, Nafa K, Ladanyi M.

Semin Diagn Pathol. 2008 Nov;25(4):288-94. Review.

PMID:
19013894
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk